Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD

Inclusion Criteria: 1. Ambulatory male or female participants with age ≥ 50 years at the time of screening 2. Capable of understanding and giving written informed consent 3. Primary or recurrent (anti-vascular endothelial growth factor naïve) active choroidal neovascularization (CNV) lesions involving the foveal center secondary to AMD 4. Best corrected visual acuity (BCVA) between 20/40 and 20/200 (Snellen equivalent) in the study eye, using ETDRS testing 5. Willingness and ability to undertake all scheduled visits and assessments Exclusion Criteria: 1. Known hypersensitivity to ranibizumab or any of the components of study medication 2. Known history of allergy to fluorescein dye 3. Scar, fibrosis, or atrophy involving the center of the fovea in the study eye 4. Subretinal hemorrhage in the study eye that involves the center of the fovea 5. Uncontrolled glaucoma 6. Use of prohibited treatments Other In-/Exclusion criteria may apply